ChemoCentryx to Host Virtual R&D Day on April 14, 2021
April 07, 2021 08:30 ET | Source: ChemoCentryx, Inc. ChemoCentryx, Inc. Mountain View, California, UNITED STATES
MOUNTAIN VIEW, Calif., April 07, 2021 (GLOBE NEWSWIRE) ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that it will host a virtual R&D Day on Wednesday, April 14, 2021 beginning at 12:30 p.m. ET. The event will feature a panel of key opinion leaders, a testimonial from a patient living with ANCA-associated vasculitis and members of the ChemoCentryx Management team. The event will focus on the Company’s upcoming milestones and developments in key pipeline programs.
Presenters:
Tausif (“Tosh”) Butt, Executive Vice President and Chief Operating Officer of ChemoCentryx
ChemoCentryx Inc (CCXI) Q4 2020 Earnings Call Transcript
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
ChemoCentryx to Present at Two Upcoming Investor Conferences
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ChemoCentryx and VFMCRP Provide Topline Results from ACCOLADE Trial of Avacopan in C3 .
ChemoCentryx, Inc.December 21, 2020 GMT
As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by eGFR compared to placebo over 26 weeks of blinded treatment
The change from baseline to Week 26 in C3 Glomerulopathy Histologic Index (C3G HI) for Disease Activity (primary endpoint) was not statistically different between the two treatment groups, while the C3G HI for Disease Chronicity (measuring progression of fibrosis) shows significant benefit for avacopan versus placebo
December 22, 2020 healthcare
VFMCRP and ChemoCentryx Provide Topline Results From ACCOLADE Trial of Avacopan in C3 Glomerulopathy Including Improved Estimated Glomerular Filtration Rate (eGFR)
Regulatory News:
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and ChemoCentryx, Inc. today announced topline data from the ACCOLADE clinical study, the largest, randomized, blinded, placebo-controlled phase-II trial in the ultra-rare kidney disease C3 glomerulopathy (C3G) to date, which evaluated avacopan for the treatment of that disorder. Avacopan is a first-in-class, orally-administered selective inhibitor of the complement C5a receptor.
Patients in the multi-center ACCOLADE clinical trial were randomized to receive either 30mg of avacopan twice daily (BID) or placebo for 26 weeks in a double-blind manner. The primary endpoint of the study was defined as the change from baseline in the C3G histologic index for disease activity, as determined by a blinded anal